[Clinical efficacy evaluation of shuangshen tongguan capsule on acute myocardial infarction patients after direct percutaneous coronary intervention].
To evaluate the therapeutic efficacy of Shuangshen Tongguan Capsule (STC) on acute myocardial infarction (AMI) patients after direct percutaneous coronary intervention (PCI). Using a randomized controlled method, AMI patients with elevated ST segment after successful direct PCI were randomly assigned to the control group (62 cases) and the treatment group (67 cases). On the basis of the standard Western medical treatment, patients in the treatment group took STC, while those in the control group took STC placebos, 4 pills each time, three times daily. The Chinese medicine syndrome integrals, the cardiac function in the resting and loading states, the microcirculation perfusion rate, and the changes of Seattle Angina Scale score were evaluated after 6 months of treatment. Five cases were lost, accounting for 3.88%. Six months later the Chinese medicine syndrome integrals obviously decreased, the efficacy of Chinese medicine syndrome was enhanced, the LVEF in the loading state and the percentage of normal myocardium obviously increased, anterior myocardial infarction segments with increased k value of the microcirculation perfusion increased, the total score of Seattle Angina score, the satisfactory degree of the treatment, and the integrals for the disease recognition degree were significantly enhanced (all P<0.05). STC could improve the angina symptoms of AMI patients after direct PCI and elevate their heart functions. It has certain roles in improving microcirculation perfusion of myocardium, thus elevating patients' quality of life.